PMC:7161517 / 21857-22157 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T130","span":{"begin":175,"end":181},"obj":"Body_part"},{"id":"T131","span":{"begin":182,"end":191},"obj":"Body_part"}],"attributes":[{"id":"A130","pred":"fma_id","subj":"T130","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A131","pred":"fma_id","subj":"T131","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"y arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T91","span":{"begin":11,"end":23},"obj":"Disease"}],"attributes":[{"id":"A91","pred":"mondo_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"}],"text":"y arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T218","span":{"begin":64,"end":72},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T219","span":{"begin":175,"end":181},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"y arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T267","span":{"begin":209,"end":222},"obj":"Chemical"}],"attributes":[{"id":"A267","pred":"chebi_id","subj":"T267","obj":"http://purl.obolibrary.org/obo/CHEBI_86267"}],"text":"y arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T761","span":{"begin":59,"end":63},"obj":"G_3;PG_10;PR:000003622"},{"id":"T762","span":{"begin":117,"end":124},"obj":"UBERON:0000948"},{"id":"T763","span":{"begin":175,"end":181},"obj":"UBERON:0001969"},{"id":"T764","span":{"begin":209,"end":222},"obj":"CHEBI:86267;CHEBI:86267"},{"id":"T765","span":{"begin":285,"end":290},"obj":"UBERON:0002113"},{"id":"T25938","span":{"begin":6,"end":13},"obj":"UBERON:0000948"},{"id":"T79570","span":{"begin":110,"end":120},"obj":"UBERON:0002349"},{"id":"T17295","span":{"begin":138,"end":145},"obj":"UBERON:0000948"},{"id":"T7913","span":{"begin":154,"end":170},"obj":"UBERON:0004535"},{"id":"T31024","span":{"begin":190,"end":196},"obj":"UBERON:0000479"},{"id":"T80939","span":{"begin":245,"end":249},"obj":"G_3;PG_10;PR:000003622"},{"id":"T64668","span":{"begin":250,"end":254},"obj":"PR:000036013"}],"text":"y arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion"}

{"project":"LitCovid-PubTator","denotations":[{"id":"950","span":{"begin":59,"end":63},"obj":"Gene"},{"id":"953","span":{"begin":94,"end":100},"obj":"Chemical"},{"id":"954","span":{"begin":209,"end":222},"obj":"Chemical"}],"attributes":[{"id":"A950","pred":"tao:has_database_id","subj":"950","obj":"Gene:59272"},{"id":"A954","pred":"tao:has_database_id","subj":"954","obj":"MESH:C002744"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"y arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion"}

{"project":"2_test","denotations":[{"id":"32305401-29903860-55252979","span":{"begin":74,"end":76},"obj":"29903860"}],"text":"y arterial hypertension, which is characterized by reduced ACE2 activity (58). Treatment with rhACE2 showed improved cardiac output that coincided with maximum suppression of plasma cytokines and reduction in nitrotyrosine levels, improved peripheral vascular resistance, and improved renal perfusion"}